CPTI-L Inhibitors
CPTI-L inhibitors, short for Carnitine Palmitoyltransferase I Long Chain inhibitors, belong to a specialized class of chemical compounds that play a crucial role in regulating fatty acid metabolism within cells. Fatty acids are essential biomolecules used for energy production in various tissues, including muscles and the liver. The CPTI-L enzyme is a key player in this process, primarily found in the mitochondria, where it facilitates the entry of long-chain fatty acids into the mitochondria for β-oxidation, a process that ultimately generates ATP (adenosine triphosphate), the cell's primary energy currency.
CPTI-L inhibitors, as the name suggests, are compounds designed to hinder or modulate the activity of the CPTI-L enzyme. By doing so, they can potentially influence the rate at which long-chain fatty acids are transported into the mitochondria, thereby impacting the overall energy balance within the cell. This modulation of fatty acid metabolism can have implications in various biological contexts, such as cellular energy regulation, lipid homeostasis, and the management of metabolic disorders. Understanding the mechanisms by which CPTI-L inhibitors interact with the enzyme is crucial for gaining insights into how these compounds might be applied in research and potentially contribute to advancements in our understanding of cellular metabolism and its various regulatory pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(+)-Etomoxir sodium salt | 828934-41-4 | sc-215009 sc-215009A | 5 mg 25 mg | $148.00 $496.00 | 3 | |
Etomoxir inhibits CPT1-L by irreversibly binding to its active site, preventing the transfer of long-chain fatty acids into mitochondria for β-oxidation. This disruption impairs cellular energy production and can be used to target cancer cells reliant on fatty acid oxidation. | ||||||
rac Perhexiline Maleate | 6724-53-4 | sc-460183 | 10 mg | $184.00 | ||
Perhexiline inhibits CPT1-L indirectly by reducing the mitochondrial membrane potential, thereby reducing the driving force for fatty acid uptake into mitochondria. This helps manage angina and heart failure by limiting myocardial fatty acid oxidation. | ||||||
Triacsin C Solution in DMSO | 76896-80-5 | sc-200574 sc-200574A | 100 µg 1 mg | $149.00 $826.00 | 14 | |
Triacsin C is a natural product that inhibits CPT1-L by blocking the formation of acyl-CoA, a necessary substrate for fatty acid transport into mitochondria. It acts as a potent anti-cancer agent by disrupting lipid metabolism. | ||||||
UK 5099 | 56396-35-1 | sc-361394 sc-361394A | 10 mg 50 mg | $154.00 $633.00 | 5 | |
UK5099 inhibits CPT1-L by blocking the carnitine/acylcarnitine transporter, preventing the transport of fatty acids into mitochondria. It is a valuable tool in research to study fatty acid metabolism. | ||||||
C75 (racemic) | 191282-48-1 | sc-202511 sc-202511A sc-202511B | 1 mg 5 mg 10 mg | $71.00 $202.00 $284.00 | 9 | |
C75 inhibits CPT1-L indirectly by activating the enzyme fatty acid synthase (FAS), which leads to reduced fatty acid oxidation. It has potential anti-cancer properties. | ||||||
Ranolazine | 95635-55-5 | sc-212769 | 1 g | $107.00 | 3 | |
Ranolazine inhibits CPT1-L by reducing the uptake of long-chain fatty acids into the mitochondria, thereby decreasing myocardial oxygen consumption and helping manage angina. | ||||||
Ethacrynic acid | 58-54-8 | sc-257424 sc-257424A | 1 g 5 g | $49.00 $229.00 | 5 | |
Etacrynic acid inhibits CPT1-L by interfering with carnitine binding and transport, leading to reduced fatty acid oxidation. It has been explored for its potential use in cancer therapy. | ||||||
A 922500 | 959122-11-3 | sc-203793 | 10 mg | $265.00 | 2 | |
A922500 is a reversible CPT1-L inhibitor that impedes the binding of fatty acids to the enzyme, reducing their transport into mitochondria. It has potential applications in metabolic disorders and cancer therapy. | ||||||